The University Capital Steering Committee have given approval for the CBF extension to progress to RIBA Work Stage C. The planned extension will give the CBF additional 470 m2 of space including two new cleanroom suites and fill & finish station to cope with the increasing demand to manufacture a variety of novel products (e.g. adenovirus vaccines, virus like particles, proteins, ATMPs). The extension is also an excellent opportunity to upgrade the existing plant and equipment to state of the art facilities and ensure that we continue to meet EU GMP requirements.

extension plan